The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2025

Filed:

Apr. 27, 2022
Applicant:

Morehouse School of Medicine, Atlanta, GA (US);

Inventors:

Michael Powell, Douglasville, GA (US);

Erick Vidjin' Agnih Gbodossou, Dakar-Etoile, SN;

Assignee:

MOREHOUSE SCHOOL OF MEDICINE, Atlanta, GA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 36/42 (2006.01); A01N 63/50 (2020.01); A01P 1/00 (2006.01); A61K 31/352 (2006.01); A61K 33/30 (2006.01); A61K 38/47 (2006.01); A61P 31/18 (2006.01); C12N 15/10 (2006.01); C12N 15/82 (2006.01); C12P 19/34 (2006.01);
U.S. Cl.
CPC ...
A61K 36/42 (2013.01); A01N 63/50 (2020.01); A01P 1/00 (2021.08); A61K 31/352 (2013.01); A61K 33/30 (2013.01); A61K 38/47 (2013.01); A61P 31/18 (2018.01); C12N 15/1096 (2013.01); C12N 15/8283 (2013.01); C12P 19/34 (2013.01); C07K 2319/01 (2013.01);
Abstract

The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.


Find Patent Forward Citations

Loading…